These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 29247268)

  • 21. Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin.
    Riess H; Becker LK; Melzer N; Harenberg J
    Blood Coagul Fibrinolysis; 2014 Dec; 25(8):838-44. PubMed ID: 25004024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticoagulation for COVID-19 Patients: A Bird's-Eye View.
    Kreidieh F; Temraz S
    Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?
    Áinle FN; Kevane B
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):201-212. PubMed ID: 33275736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence-Based Therapies for Pharmacologic Prevention and Treatment of Acute Deep Vein Thrombosis and Pulmonary Embolism.
    Jacobs B; Henke PK
    Surg Clin North Am; 2018 Apr; 98(2):239-253. PubMed ID: 29502769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deep venous thrombosis.
    López JA; Kearon C; Lee AY
    Hematology Am Soc Hematol Educ Program; 2004; ():439-56. PubMed ID: 15561697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
    Prandoni P; Carnovali M; Marchiori A;
    Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT).
    Bauersachs R; Gerlach HE; Heinken A; Hoffmann U; Langer F; Noppeney T; Pittrow D; Klotsche J; Rabe E
    Eur J Vasc Endovasc Surg; 2021 Aug; 62(2):241-249. PubMed ID: 34210599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The current landscape of treatment options for venous thromboembolism: a focus on novel oral anticoagulants.
    Hull RD; Gersh MH
    Curr Med Res Opin; 2015 Feb; 31(2):197-210. PubMed ID: 25299352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medical therapy in venous thromboembolism.
    Eichinger S; Kyrle PA
    Semin Respir Crit Care Med; 2012 Apr; 33(2):186-90. PubMed ID: 22648491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on extended treatment for venous thromboembolism.
    Peñaloza-Martínez E; Demelo-Rodríguez P; Proietti M; Soria Fernández-Llamazares G; Llamazares-Mendo C; Álvarez-Sala Walther L; Marra AM; Del Toro-Cervera J
    Ann Med; 2018 Dec; 50(8):666-674. PubMed ID: 30345825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral anticoagulant therapy in venous thromboembolism.
    Cosmi B; Palareti G
    Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism.
    Bauersachs R
    Thromb Res; 2016 Aug; 144():12-20. PubMed ID: 27263046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticoagulation Beyond 3 to 6Months: What Does the Data Tell Us?
    Carman TL
    Prog Cardiovasc Dis; 2018; 60(6):607-612. PubMed ID: 29634958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deep vein thrombosis and pulmonary embolism.
    Di Nisio M; van Es N; Büller HR
    Lancet; 2016 Dec; 388(10063):3060-3073. PubMed ID: 27375038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The optimal duration of anticoagulant treatment following pulmonary embolism].
    Couturaud F
    Rev Mal Respir; 2011 Dec; 28(10):1265-77. PubMed ID: 22152935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Benefit/risk ratio analysis from a possible anticoagulation of asymptomatic deep venous thrombosis in major orthopedic surgery].
    Barrellier MT; Samama CM
    J Mal Vasc; 2013 May; 38(3):178-84. PubMed ID: 23415379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended anticoagulation therapy for the primary and secondary prevention of venous thromboembolism.
    Blanchard E; Ansell J
    Drugs; 2005; 65(3):303-11. PubMed ID: 15669876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idraparinux versus standard therapy for venous thromboembolic disease.
    ; Buller HR; Cohen AT; Davidson B; Decousus H; Gallus AS; Gent M; Pillion G; Piovella F; Prins MH; Raskob GE
    N Engl J Med; 2007 Sep; 357(11):1094-104. PubMed ID: 17855670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs.
    Caprini JA; Tapson VF; Hyers TM; Waldo AL; Wittkowsky AK; Friedman R; Colgan KJ; Shillington AC;
    J Vasc Surg; 2005 Oct; 42(4):726-33. PubMed ID: 16242561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis.
    Dager WE; King JH; Branch JM; Chow SL; Ferrer RE; Pak S; Togioka PY; White RH
    Ann Pharmacother; 2005; 39(7-8):1182-7. PubMed ID: 15956232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.